Authors
Derek De-Rui Huang, James Chih-Hsin Yang
Published in
Cancer cell. Oct 16, 2026. Epub Oct 16, 2026.
Abstract
EGFR PACC-mutant non-small cell lung cancer (NSCLC) has limited treatment options. In this issue of Cancer Cell, Le et al. report preclinical profiles and promising systemic and intracranial efficacy of the broad-spectrum CNS-penetrant tyrosine kinase inhibitor firmonertinib in PACC-mutant NSCLC, supporting its further clinical development in this challenging mutation class.
PMID:
42887496
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 28
- Comments 0